NewEdge Wealth’s Axsome Therapeutics AXSM Stock Holding History

NewEdge Wealth’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$851K	Sell	3,476 -187	-5%	-$40.6K	0.01%	703
2026 Q1	$619K	Buy	+3,663	New	+$633K	0.01%	752

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

NewEdge Wealth's AXSM Position: Q2 2026 in Review

NewEdge Wealth reduced its Axsome Therapeutics (AXSM) stake by 5.1% in Q2 2026, selling an estimated $40.6K and leaving 3,476 shares worth $851K. The position accounts for 0.01% of the portfolio, ranked #703.

NewEdge Wealth first reported a position in AXSM in Q1 2026 and has held it in 2 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

NewEdge Wealth held 3,476 shares of Axsome Therapeutics worth $851K as of Q2 2026.
NewEdge Wealth sold 187 Axsome Therapeutics shares in Q2 2026, an estimated $40.6K.
Axsome Therapeutics made up 0.01% of NewEdge Wealth's portfolio in Q2 2026, its #703 holding.
NewEdge Wealth first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 2 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on NewEdge Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.